United States · Platforms & data · MarketBeat
Vertex Pharmaceuticals Prepares for Key Kidney Drug Decision as Pipeline Readouts Loom

Detailed summary
Vertex Pharmaceuticals (NASDAQ:VRTX) is preparing for a Nov. 30 U.S. regulatory decision on its kidney disease treatment povetacicept, while awaiting clinical results across kidney disease, chronic pain and other conditions, company executives said at a UBS investor event. Susie Lisa, Vertex’s seni
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)




